Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL198461 | 0.87 | CSNK2A2 (0.52) | CSNK2A2CSNK2BCSNK2A1CSNK2A3CYP2D6 | |
| SCHEMBL2776956 | 0.85 | CSNK2A2 (0.50) | CSNK2A2CSNK2BCSNK2A1CSNK2A3CYP2D6 | |
| Ethane SCHEMBL3687850 | 0.85 | CSNK2A2 (0.50) | CSNK2A2CSNK2BCSNK2A1CSNK2A3CYP2D6 | |
| SCHEMBL11382359 | 0.85 | CSNK2A2 (0.50) | CSNK2A2CSNK2BCSNK2A1CSNK2A3CYP2D6 | |
| SCHEMBL3563199 | 0.85 | PPARA (0.38) | CSNK2A2CSNK2BCSNK2A1CSNK2A3CYP2D6 | |
| SCHEMBL16166663 | 0.80 | NR1H2 (0.51) | — | |
| SCHEMBL49546 | 0.79 | — | — | |
| SCHEMBL3561165 | 0.79 | GABRA1 (0.44) | CSNK2A2CSNK2BCSNK2A1CSNK2A3CYP2D6 | |
| SCHEMBL715213 | 0.79 | MEN1 (0.47) | CYP2D6MAPTL3MBTL1NPSR1LMNA | |
| SCHEMBL16933904 | 0.77 | CSNK2A2 (0.42) | CSNK2A2CSNK2BCSNK2A1CSNK2A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653960-A4 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN INC (US) | 2008-11-26 | — | — | EP | claimed |
| EP-1653960-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN INC. (US) | 2006-05-10 | — | — | EP | claimed |
| US-20050215526-A1 | Melanin concentrating hormone receptor antagonist | AMGEN, INC. | 2005-09-29 | — | — | US | claimed |
| WO-2005019167-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN, INC. (US) | 2005-03-03 | — | — | WO | claimed |
| US-7659276-B2 | Melanin concentrating hormone receptor antagonist | AMGEN, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090143405-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-7514438-B2 | Melanin concentrating hormone receptor antagonist | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1653960-A4 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN INC (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1653960-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN INC. (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050215526-A1 | Melanin concentrating hormone receptor antagonist | AMGEN, INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2005019167-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143405-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | MCHR1, MC1R, NPY1R | CSNK2A2 1870/4885CSNK2B 2235/4885CSNK2A1 1976/4885 |
| US-20050215526-A1 | Melanin concentrating hormone receptor antagonist | MCHR1, MC1R, NPY1R | CSNK2A2 1870/4885CSNK2B 2235/4885CSNK2A1 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.